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ABSTRAK 
OBJEKTIF: Mengenalpasti faktor demografi , ciri-ciri klinikal, penyebab serta 
komplikasi dan faktor-faktor risiko kematian dikalangan bayi yang matang dan 
mempunyai berat badan;:::: 2.50 Kg yang mendapat bantuan ventilasi. 
METODOLOGI: Satu kajian prospektif telah dijalankan dari 1 hb. Julai-
31 hb.Disember 2000 di Hospital Kota Bharu dan dari 1 hb. Januari-31 hb. 
Disember 2001 di Hospital Universiti Sains Malaysia .Bayi -bayi yang 
memenuhi kriteria yand ditetapkan akan dimasukkan kedalam kajian.Segala 
dater-data yang berkaitan seperti faktor demografi, ciri-ciri klinikal, komplikasi 
dan kematian akan direkodkan. Analisa statistik akan dilakukan bagi 
mendapatkan faktor-faktor risiko kematian di kalangan bayi-bayi matang yang 
mendapat bantuan ventilasi. 
KEPUTUSAN: Jumlah bayi lelaki yang memerlukan bantuan ventilasi adalah 
lebih ramai (60.9%) berbanding dengan bayi perempuan (39.1 °/o). Lebih dari 
50o/o bayi yang memerlukan bantuan ventilasi di kalangan golongan kategori 
berat 3.00-3.49 Kg. Penyebab utama kepada perlunya bantuan ventilasi ini 
ialah asfiksia (42°/o), sindrom aspirasi mekonium (28°/o), radang paru-paru 
kongenital (21 °/o) dan sepsis (9°/o). Berbagai komplikasi berlaku kepada bayi-
bayi ini termasuk tekanan darah yang rendah,sawan,PPHN dan lain-lain lagi. 
Faktor risiko yang signifikan dalam menentukan kematian ialah skor Apgar 
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kurang dari 4 pad a 1 min it (p=0.001 ), pendarahan dalam kepala (p=0.009), 
PPHN (p=0.018) dan pneumothorax (p=0.036). 
KESIMPULAN: Asfiksia,sindrom aspirasi mekonium , radang paru-paru 
kongenital dan sepsis merupakan penyebab utama kepada bantuan ventilasi 
dikalangan bayi yang matang . Disamping itu juga, bayi lelaki lebih ramai yang 
memerlukan bantuan ventilasi. Kedua- dua keputusan ini setanding dengan 
kajian-kajian yang dibuat di negara lain.Komplikasi yang berlaku dikalangan 
bayi-bayi ini adalah berkait rapat dengan masalah asfiksia. Pengurangan kadar 
asfiksia akan dapat mengurangkan kadar bantuan ventilasi dikalangan bayi-
bayi yang matang ini. 
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ABSTRACT 
Objectives:To determine the demographic profile, clinical characteristics and 
common causes of ventilation and complications among ventilated term babies 
weighing ~ 2.50 Kg and to determine the predictive factors for the outcome of 
these ventilated term babies. 
Methodology: A prospective study was conducted from 1st July 2000 until 31st 
December 2000 in Hospital Kota Bharu and from 1st January 2001 to 31st 
December 2001 in Hospital Universiti Sa ins Malaysia. All the term babies weighing 
more than or equal to 2.50 kilogram and received assisted ventilation were 
included in the study. Data regarding demographic and clinical characteristics were 
collected and all the complications that occurred during ventilation and the final 
outcome were documented. The predictors that determine the outcome were 
analysed using multiple logistic regression. 
Results: The proportion of male to female babies that required ventilation were 
60.9°/o and 39.1 °/o respectively and more than 50°/o of babies weighed between 
3.00 -3.49 Kg. The most common reasons for ventilation among term babies were 
asphyxia (42o/o), MAS (28%,), congenital pneumonia (21 °/o) and sepsis {9°/o). Many 
complications occurred while on ventilation like hypotension, seizures, PPHN and 
others. The significant predictors that determined the outcome of ventilated babies 
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Were Apgar score less than 4 at 1 minute (p=0.001 ), intracranial haemorrhage 
(p=0.009), PPHN (p= 0.018) and pneumothorax (p=0.036). 
Conclusions: Asphyxia, MAS, congenital pneumonia and sepsis were the most 
common cause of ventilation and assisted ventilation was common among male 
babies. These results corresponded well to other studies. The complications that 
occured were mostly related to asphyxia and most causes of death were 
preventable. 
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INTRODUCTION 
The outcome of preterm babies has been well·documented and described but not 
the "bigger" size babies. These bigger size term babies were considered low risk 
babies but if they require admission to the neonatal intensive care unit, they must 
be managed 9ggressively. It is important to identify those at ris~ among them, so 
that we can anticipate the problems that might occur in high risk cases and prevent 
further complications. However not many studies were conducted looking at this 
problem specifically among those that received artificial ventilation. In view of these 
discrepancies in the documented data concerning term babies who required 
ventilatory support, we conducted this study to look at the clinical characteristics, 
outcome and predictors for their outcome. 
For all babies, birth weight is determined by two major factors that are duration of 
gestation and intrauterine growth rate. (Kramer, 1987). The lowest risk of neonatal 
mortality occurs among infants with a birth weight of 3000 to 4000 g whose 
gestational age is between 38 and 42 weeks. Nevertheless, approximately 40°/o of 
all perinatal deaths occur after 37 weeks of gestation in infants weighing 2500 g or 
more. Many of these deaths occur in the period immediately after birth and are 
more readily preventable than those of smaller and more immature infants. 
(Dawodu and Effiong, 1985). 
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Neonatal care can be categorized into three levels of facilities: 
(1) Levell facilities can provide care for normal, healthy newborns with 
the capacity to stabilize sick infants for transport. 
(2) Level II facilities have the capacity for an intermediate level of care of 
more complicated cases including the administration of intravenous fluids 
continuous positive airway pressure , short term ventilation and treatment 
of pneumothoraces. 
' 
(3) Level Ill facilities contains a neonatal intensive care unit (NICU) capable of 
complete care of the high risk foetus , neonates and mothers, also have 
n_eonatologist and can provide specialized neonatal surgery. 
(Berg, 1989). 
The major determinants of NICU admission among normal birth weight infants 
include congenital anomalies (21.6o/o), prematurity despite normal birth weight 
(22%,) and acute complications during the neonatal period. Among those that were 
admitted, only 59°/0 received active therapy, whereas the remainder received only 
intensive monitoring. (Gray JE, 1996). 
Assisted ventilation is a complex technique that has been responsible for much of 
the improvement in neonatal morbidity and mortality during the last ten to fifteen 
Years. In unskilled hands, it can be dangerous with complications as high as thirty 
Percent (30o/o ). It requires a constantly available medical and nursing team that can 
supervise the care of critically ill infants arou~d the clock. (Krauss AN, 1980). 
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A certain number of infants were able to survive without assisted ventilation. 
Therefore, whenever the decision is made to begin assisted ventilation, the risk 
must be carefully weighed against the benefits to be gained. Sometimes the 
decision to begin assisted ventilation cannot be based on blood gases that are 
abnormal. (Krauss AN, 1980). 
The main function of assisted ventilation is to treat the respiratory failure. In any 
patients, regardless of age, the respiratory failure can take two forms. In one form, 
the infants are apnoeic and assisted ventilation is undertaken simply because the 
infants cannot breathe without assistance and lungs are often normal. The second 
group of infants requiring ventilation is those in whom failure of the pulmonary 
exchanges mechanism has occurred. The infants manifest as hypoxemia, 
hypercapnea and respiratory failure. (Kraus AN, 1980) 
Assisted ventilation consists of supplying an additional volume of air to the lungs 
during a given period of time sufficient to remove the carbon dioxide that is 
produced by the metabolic process during that particular interval and to supply the 
oxygen needed in order to allow these metabolic processes to continue without 
excessive production of lactic acids. (Kraus AN 1980). 
The earliest manifestation of impaired respiratory function is often hypoxemia 
(partial pressure oxygen < 50mmHg) which is usually managed by the addition of 
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supplemental oxygen alone to ambient air. If hypoxemia progresses or respiratory 
acidosis developes, artificial ventilation with a mechanical ventilator should be 
initiated. (Kraus AN 1980). 
In infants who had meconium aspiration syndrome, they were prone to develop 
respiratory failure that can be recognized based on these parameters; partial 
pressure oxygen (Pa02) less than 50mmHg in fraction inspired oxygen (fi02) 1.00, 
partial pressure carbon dioxide (PaC02) more than 75mmHg or recurrent apnoea. 
During the period of assisted ventilation, an attempt was made to keep partial 
pressure oxygen (Pa02) between 50-90 mmHg and partial pressure carbon 
dioxide (PaC02) less than 65 mmHg. (Vidyasagar, 1975). 
The infant will be weaned down from the respirator once the clinical and 
biochemical parameters were permissible, since ventilation is a known risk for 
infection. Apart from that, its complications can compromise systemic circulation in 
several ways. (Srimarthi G, 2000). 
1. Causes of ventilation 
Preterm infants with respiratory distress syndrome or term infants with various 
causes usually require assisted ventilation 
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1.1 Perinatal asphyxia 
Throughout the world, perinatal asphyxia remains an important cause of perinatal 
acquired brain injury in full term infants and produces a huge burden of worldwide 
disability. The incidence of death or severe neurological impairment following 
perinatal asphyxia is 0.5 to 1.0 per 1000 live births in developed countries. 
(Finer, 1981 ). 
Mac Donald (1980) reported that the incidence of asphyxia was indirectly related to 
the gestational age and weight. It was as low as 0.4°/o in infants > 38 weeks and 
increased up to 62.3°/o in infants < 27 weeks. Concerning birth weight, the 
incidence was 0.5o/o and 72.3°/o in infants >2500 gram and < 750 gram 
respectively. Thornberg (1995) stated that the incidence of perinatal asphyxia in 
Sweden was 2.9 per 1000 live births, but if premature babies were included, the 
incidence went up as high as 17 per 1000 live births. 
In developing countries, perinatal asphyxia appears to be more common. Boo NY 
et al (1992) reported from their study at Maternity Hospital Kuala Lumpur that the 
incidence of perinatal asphyxia was 18.7 per 1000 live birth. However, the 
incidence was significantly more common in the neonates weighing less than 
2500g ( 48.3 per 1000 live births) than those weighing 2500g or more (15.3 per 
1000 live births with p<0.001 ). Meanwhile, AI Alfy (1990) from Kuwait reported that 
the incidence of perinatal asphyxia was 9.4 per 1000 live birth. In Nigeria, the 
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incidence was higher with value of 26.5 per 1000 live births as stated by Airede 
(1991 ). All the above studies using Apgar score as criteria for diagnosing perinatal 
-asphyxia but Boo NY et al also included the intrapartum signs of abnormal foetal 
heart rate. 
The definition of asphyxia is still debatable. Avery (1981) defin~s asphyxia as 
a condition that occurs when the organ of gas exchange fails. The failure of the 
organ of gas exchange, whether it was the lungs or placenta is associated with 
abnormal blood gas results; that is a rise in partial pressure carbon dioxide (Pa 
C02) and a fall in partial pressure oxygen (Pa02), ultimately leading to a decrease 
in pf-1 value. 
The American Academy of Paediatrics (AAP) (1986) suggested that three criterias 
should be met in order to diagnose asphyxia: 
( 1) Apgar score of 0-3 at 1 0 minutes 
(2) Early neonatal seizure 
(3) Prolonged hypotonia. 
The presence of metabolic acidosis in cord blood further helps to confirm 
suspected hypoxia and multiple organ dysfunctions in the early neonatal period. 
Jacobs MM (1989) defined asphyxia as combinations of hypoxemia, hypercarbia 
and metabolic acidosis. 
6 
There is no single measurement for consistently qualifying asphyxia. The Apgar 
score was the first attempt at a systematic assessment. It is useful but has 
limitations because of maternal anaesthetic, sedatives, maternal drugs, foetal 
sepsis and central nervous system pathology that can lower down the Apgar score. 
(American Academy of Paediatrics , 1986). 
The scoring of Apgar score should continue every 5 minutes until the score 
increases to seven or above and the length of time taken to reach a score of seven 
is a rough sign of severity of asphyxia. (Jacob MM, 1989) . 
. 
Hypoxic ischemic encephalopathy (HIE) is a clinical syndrome when asphyxia is 
followed by an abnormal neonatal behaviour. The severity of HIE can be classified 
to mild, moderate, and severe according to criteria of Sarnat and Sarnat (1 976) 
modified by Fenichel (1 983). 
(1) Mild HIE is characterized by hyper alertness and irritability, normal muscle 
tone, normal or hyperactive reflexes, ankle clonus and no seizure. 
(2) Moderate HIE includes lethargy, decreased spontaneous movement, proximal 
muscle weakness, depressed primitive reflexes and seizures. 
(3) Severe HIE includes stupor or coma, markedly reduced muscle tone or 
flaccidity and absent primitive reflexes. Seizures are often frequent and difficult 
to control but may also be totally absent. 
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The hypoxic ischemic encephalopathy may result from impaired placental gas 
exchange or blood flow from umbilical cord compression or may occur postnatally 
as a result of neonatal respiratory or cardiac compromise. The postnatal insults. 
usually account for only 1 0°/o of infants with evidence of hypoxic ischemic 
encephalopathy. (Finer NN 1981 ). 
The incidence of significant hypoxic ischemic encephalopathy was 3.6/1000 live 
births and death of 1.3/1000 live birth in term infants. (Finer NN, 1981 ). 
In a study by Finer NN (1981 ), ninety-five singleton term infants with hypoxic 
ischemic encephalopathy were studied, 34.7°/o of them required ventilation with 
18.9. 0/o had intracranial haemorrhage. 
Mildly asphyxiated infant without underlying lung disease would respond quickly to 
initial lung inflation and will need little or no assisted ventilation or oxygen therapy. 
This transient post asphyxia event is probably due to ischemic lung injury. (Finer 
NN, 1981 ). 
There are four potential problems with the systemic circulation in the asphyxiated 
infant. These occur at different times during the course of resuscitation. There is 
cardiac arrest or severe myocardial failure at birth, hypovolemic shock, interference 
with systemic circulation from complication of ventilation and postasphyxial 
cardiomyopathy. (Jacobs MM , 1989). 
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An additional important factor in managing asphyxiated infants is hypoglycaemia, 
which may occur quickly in infants during convalescing period. Repeated 
screenings of blood glucose will detect this condition. Therefore, it is important to 
check the blood sugar as soon as the initial resuscitation measures are completed. 
(Jacob MM, 1989). 
1.2 Meconium aspiration syndrome (MAS) 
Meconium is a viscous green liquid that consists of gastrointestinal tract secretions: 
bile, "bile acids, mucus, pancreatic juice, cellular debris, amniotic fluid, swallowed 
vernix, lanugo and blood. It's present in the foetal gastrointestinal tract starting 
from the 1oth to 16th week of gestation. (Holtzman et al, 1989). 
Initially, the passage of meconium in utero was thought to be solely related to 
foetal asphyxia. However, many studies done have failed to show a consistent 
effect of asphyxia on the intrauterine passage of meconium. (Katz and Bowes, 
1992).The intrauterine passage of meconium is not only thought to be related to 
asphyxia alone, but also the result of physiological gastrointestinal maturity. 
The passage of meconium in most cases is probably a physiological event related 
to increasing maturity of the foetus; however, it is possible that it will at times occur 
as the result of foetal hypoxia and acidosis. (Miller FC 1975). It is probable that 
9 
whenever meconium happens to be present in the amniotic fluids, foetal 
hypoxemia plus acidosis can result in gasping and consequent in utero aspiration 
of meconium. (Miller, 1975, Block, 1981 ). 
The passage of meconium by the foetus is believed to be a maturational event. In 
a study by Matthews and Warshaw (1979) the majority of meconium staining of 
the amniotic fluid (MSAF) occurred in term newborns (98.4°/o) and none in those 
less than 34 weeks of gestation. Myelination of the neural plexus of the 
gastrointestinal tract progresses throughout gestation and as the nervous system 
continues to mature in utero, parasympathetic stimuli are propagated to initiate 
defecation, thus resulting in intrauterine passage of meconium. (Grand RJ, 1976). 
The pathophysiology of meconium aspiration syndrome is related to mechanical 
ob~truction of the airway and inactivation of the surfactant system by the 
meconium leading to pulmonary atelectasis .This is followed by the development of 
chemical pneumonitis that contributes to further pulmonary damage. (Lam BCC, 
1999). 
Meconium staining of amniotic fluid occurred in between 9 to 14 percent of all 
pregnancies at the time of delivery. Indeed, the incidence can be as high as 44 
percent in post date pregnancies. (Knox GE, 1979). Meconium aspiration 
syndrome is a severe respiratory illness affecting mostly full term babies and often 
requiring assisted ventilation and oxygen. (Swaminathan, 1989). 
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line results in increased activation of the transcription factor NF-B, with consequent 
increased release of interleukin-8 in response to endotoxin and increased expression of 
intercellular adhesion molecule I, providing a molecular mechanism for the amplification 
during the inflammatory response (54). 
Although smoking is the principal cause of COPD, quitting smoking does not appear to 
result in resolution of the inflammatory response in the airways (55,56). This suggests 
that there are perpetuating mechanisms that maintain the chronic inflammatory process 
once it has become established. Such mechanisms may account for the presentation of 
COPD in patients who have stopped smoking many years before their first symptoms 
develop. The mechanisms of disease persistence are currently unknown. 
f) Acute Exacerbations 
Although acute exacerbations of COPD as defined by increased symptoms and worsening 
lung function are a common cause of hospital admission, their mechanism is far from 
clear. Acute exacerbations may be prolonged and may have a profound effect on the 
quality of life (57). It was always assumed that the increased amount and purulence 
sputum were due to bacterial infection of the respiratory tract. It is now evident that many 
exacerbations in COPD, as in asthma, are due to upper respiratory tract viral infections 
(such as rhinovirus infection) and to environmental factors, such as air pollution and 
temperature (58,59). There is an increase in neutrophils and in the concentrations of 
interleukin-6 and interleukin-8 in sputum during an exacerbation, and patients who have 
frequent exacerbations have higher levels of interleukin-6, even when COPD is stable 
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(60). Bronchial biopsies show an increase in eosinophils during exacerbations in patients 
with mild COPD (24) but there is no increase in sputum eosinophils during exacerbations 
in patients with severe COPD (60). An increase in markers of oxidative stress and 
exhaled nitric oxide, presumably reflecting increased airway inflammation, is observed 
during exacerbations (39,61,62). 
g) TreatmentofCOPD 
Smoking cessation is the only measure that will slow the progression of COPD, as 
confirmed in the large Lung Health Study (63). Nicotine-replacement therapy (by gum, 
transdermal patch, or inhaler) provides help to patients in quitting smoking (64) but the 
use of the recently introduced drug bupropion, a noradrenergic antidepressant, has proved 
to be the most effective strategy to date. A recent controlled trial showed that after a 9-
week course of bupropion, abstinence rates were 30 percent at 12 months, as compared 
with only 15 percent with placebo. The abstinence rate was slightly improved with the 
addition of a nicotine patch (65). 
Bronchodilators are the mainstay of current drug therapy for COPD. Bronchodilators 
cause only a small (<10 percent) increase in FEV1 in patients with COPD, but these drugs 
may improve symptoms by reducing hyperinflation and thus dyspnoea, and they may 
improve exercise tolerance, despite the fact that there is little improvement in spirometric 
measurements (66). Several studies have demonstrated the usefulness of the long-acting 
inhaled 82-agonists salmeterol and formoterol in COPD (67,68,69). An additional benefit 
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of long-acting 62-agonists in COPD may be a reduction in infective exacerbations, since 
these drugs reduce the adhesion of bacteria such as Haemophilus influenzae to airway 
epithelial cells (70). 
COPD appears to be more effectively treated by anticholinergic drugs than by 62-
agonists, in sharp contrast to asthma, for which 62-agonists are more effective (71). A 
new anticholinergic drug, tiotropium bromide, which is not yet available for prescription, 
has a prolonged duration of action and is suitable for once-daily inhalation in COPD (72). 
Acute exacerbations of COPD are commonly assumed to be due to bacterial infection, 
since they may be associated with increased volume and purulence of the sputum. 
However, as noted above, it is increasingly recognized that exacerbations may be due to 
viral infections of the upper respiratory tract or may be noninfective (58) so that antibiotic 
treatment is not always warranted. A meta-analysis of controlled trials of antibiotics in 
COPD showed a statistically significant but small benefit of antibiotics in terms of 
clinical outcome and lung function (73). Although antibiotics are still widely used for 
exacerbations of COPD, methods to diagnose bacterial infection reliably in the 
respiratory tract are needed so that antibiotics are not used inappropriately. There is no 
evidence that prophylactic antibiotics prevent acute exacerbations. 
Inhaled corticosteroids are now the mainstay of therapy for chronic asthma, and the 
recognition that chronic inflammation is also present in COPD provided a rationale for 
their use in COPD. Indeed, inhaled corticosteroids are now widely prescribed for COPD, 
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and in North America they are used as frequently in patients with COPD as in those with 
asthma. However, the inflammation in COPD is not suppressed by inhaled or oral 
corticosteroids, even at high doses (34, 77). This lack of effect may be due to the fact that 
corticosteroids prolong the survival of neutrophils (78) and do not suppress neutrophilic 
inflammation in COPD. 
Approximately I 0 percent of patients with stable COPD have some symptomatic and 
objective improvement with oral corticosteroids (102). It is likely that these patients have 
concomitant asthma, since both diseases are very common. Indeed, airway hyper-
responsiveness, a characteristic of asthma, may predict an accelerated decline in FEV 1 in 
patients with COPD (14). Recent studies had found no evidence that long-term treatment 
with high doses of inhaled corticosteroids reduced the progression of COPD, even when 
treatment was started before the disease became symptomatic. 
Home oxygen therapy accounts for a large proportion of the costs of treating COPD (over 
30 percent in the United States, where expensive liquid oxygen is widely used). Long-
term oxygen therapy was justified by two large trials that showed reduced mortality and 
improvement in quality of life in patients with severe COPD and chronic hypoxemia 
(partial pressure of arterial oxygen, <55 mm Hg) (74). More recent studies have 
demonstrated that oxygen does not increase survival in patients with less severe 
hypoxemia, so that the selection of patients is important in prescribing this expensive 
therapy (75). Similarly, in patients with COPD who have nocturnal hypoxemia, nocturnal 
14 
treatment with oxygen does not appear to increase survival or delay the prescription of 
continuous oxygen therapy (76). 
Inhaled corticosteroids may slightly reduce the severity of acute exacerbations (83) but it 
is unlikely that their use can be justified in view of the risk of systemic side effects in 
these susceptible patients and the expense of using high-dose inhaled corticosteroids for 
several years. 
By contrast, two recent studies have demonstrated a beneficial effect of systemic 
corticosteroids in treating acute exacerbations of COPD, with improved clinical outcome 
and reduced length of hospitalization (84,85). The reasons for this discrepancy between 
the responses to corticosteroids in acute and chronic COPD may be related to differences 
in the inflammatory response (such as increased numbers of eosinophils) or airway 
oedema in exacerbations. 
h) Nonpharmacologic Treatments 
Noninvasive Ventilation 
The use of noninvasive positive-pressure ventilation with a simple nasal mask, which 
eliminates the necessity for endotracheal intubation, reduces the need for mechanical 
ventilation in acute exacerbations of COPD in the hospital (86) although some studies 
have shown little or no benefit (87). Uncontrolled studies have shown that noninvasive 
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positive-pressure ventilation used at home may improve oxygenation and reduce hospital 
admissions in patients with severe COPD and hypercapnoea and may improve long-term 
survival, although large, controlled trials are now needed (88). In one small, controlled 
trial, noninvasive positive-pressure ventilation was not well tolerated and produced only 
marginal benefits (89). The combination of noninvasive positive-pressure ventilation and 
long-term oxygen therapy may be more effective (90) but larger trials are needed before 
this combined therapy can be routinely recommended. 
Pulmonary Rehabilitation 
Pulmonary rehabilitation consisting of a structured program of education, exercise, and 
physiotherapy has been shown in controlled trials to improve exercise capacity and 
quality oflife among patients with severe COPD (91) and to reduce the amount of health 
care needed (92). 
Lung-Volume-Reduction Surgery 
There has been considerable interest in the surgical removal of the most emphysematous 
parts of the lung to improve ventilatory function (93,94). The reduction in hyperinflation 
improves the mechanical efficiency of the inspiratory muscles. Careful selection of 
patients after a period of pulmonary rehabilitation is essential. Patients with localized 
upper-lobe emphysema appear to do best; relatively low lung resistance during inspiration 
appears to be a good predictor of improved FEV 1 after surgery (95). Functional 
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improvements include increased FEY 1, reduced total lung capacity and functional 
residual capacity, improved function of respiratory muscles, improved exercise capacity, 
and improved quality of life (96,97). The benefits persist for at least a year in most 
patients, but careful extended follow-up is needed to evaluate the long-term benefits of 
this therapy. A large, multicenter study, the National Emphysema Treatment Trial, is now 
under way in the United States to investigate the effectiveness and cost of lung-volume-
reduction surgery in comparison with conventional therapy (98). 
Randomised trials had been published on the efficacy of systemic corticosteroid 
treatment in acute exacerbation of COPD using treatment that differed in initial dose 
(prednisolone 30mg/day, prednisone 60mg/day, hydrocortisone 600mg/day; 
methylprednisolone 2mg/kg/day to 500mg/day) and duration (3 to 56 
days)(84,85,101,103,104). It is difficult to draw any conclusion from these data as to the 
optimal dose and treatment duration of systemic steroid used in COPD exacerbations. 
This study was undertaken to look at the effectiveness of oral prednisolone 20mg daily 
for two weeks in acute exacerbation of COPD. 
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Objective 
The main objective of this study is to evaluate the effectiveness of oral corticosteroid as a 
treatment for acute exacerbation of chronic obstructive pulmonary disease (COPD) 
Hypothesis 
Oral corticosteroid is superior than placebo in improving airway obstruction in patients 
presenting with acute exacerbation of COPD 
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Methodology and Subjects 
Settings in this study 
Patients with the diagnosis of COPD presenting with acute exacerbation to casualty or 
outpatient department in Hospital Alor Setar from 1st August 1999 to 1st April 2000 were 
selected. Acute exacerbation was defined as increasing breathlessness and at least 2 of the 
following symptoms: 
I. increased cough frequency or severity 
2. increased sputum volume or purulence 
3. increased wheeze 
Inclusion criteria were 
Patients with 
• acute exacerbation of COPD 
• age 40 to 80 years 
• smoking history of at least 20 pack-years 
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Exclusion criteria 
The following patients were excluded from the study 
• History of asthma or atopy 
• Left ventricular failure 
• Clinical or radiological evidence of pneumonia 
• Had received oral corticosteroid within one month of presentation 
• Arterial blood pH less than 7.30 
Study Design 
Full medical history and physical examination were taken on admission. Blood sample 
was also taken for arterial blood gases. Sputum was collected for acid-fast bacilli direct 
smear and also for culture and sensitivity. 
Eligible patients received standard treatment with nebulised B2 agonist ( 5 mg 
Salbutamol) and an anticholinergic ( 500 ug ipratropium bromide ) every 6 hours and 
controlled oxygen therapy. Any patient who was receiving inhaled corticosteroid before 
randomization was continued on this therapy. 
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Patients were randomised to receive prednisolone 20 mg everyday or similar-appearing 
placebo (Vitamin B6) for two weeks. This particular dose of prednisolone was chosen 
because of the relatively smaller size of our local population as compared to western 
population. One study done in the United Kingdom for acute exacerbation of COPD used 
30 mg of prednisolone to compare with placebo(85). 
Randomisation was done by hospital pharmacy. The medication pack supplied by the 
pharmacy were labeled A and B. 
Spirometry was done daily before and 15 minutes after 5 mg nebulised salbutamol. A 
daily symptom score was obtained, calculated from a questionnaire completed by the 
patient. Questions were asked about breathlessness, sputum production, wheeze, 
mobility, sleep quality, cough and general well being. Patients were asked to score each 
of the symptoms from 0 (more than usual) to 5 (much worse than usual). The 
questionnaire was piloted earlier among fifty patients admitted in medical ward. 
Data were also collected about potential side effects of oral corticosteroids ( mood 
swings, heart bum and overt gastrointestinal bleeding). Patients' urine was tested daily 
for glucose. Daily morning capillary blood sugar was also done. 
Study duration was from the time of admission to the time of discharge and included a 
follow-up visit six weeks after admission. 
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The physician in charge of the patients were free to withdraw patients from this study at 
any time if they felt clinical improvements were not satisfactory. Patients were also free 
to withdraw at any time if they were not satisfied with their progress. 
The physician incharge also decided the time at which patients were medically fit for 
discharge. The patients were instructed to complete their treatment after discharge and to 
bring their treatment pack during follow-up. 
Six weeks after starting treatment, patients were recalled to repeat spirometry before and 
after 5 mg nebulised salbutamol. Their medication pack was checked to make sure the 
treatment was completed after discharge. 
Statistical Analysis 
We calculated (two means) that a sample size of 24 in each group would give us 80% 
power to detect a difference of0.05L per day in mean FEV1 between the two groups, with 
a standard deviation of 0. 0625. 
We calculated means (standard error) and used Student's t test to compare normally 
2 • 
distributed data. We used x test to compare proporttons. 
Ethical Clearance 
This study protocol was approved by local ethical committee in Hospital Alor Setar 
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Results 
A total of seventy five patients were screened and admitted in Hospital Alor Setar during 
the study. Sixty two patients met the inclusion criteria. Reasons for exclusion included 
the use of oral corticosteroid in the past four weeks, evidence of pneumonia and 
pulmonary tuberculosis. Two patients were confirmed to have pulmonary tuberculosis. 
(Figure I) 
Nine patients refused to sign consent of which three of them refused oral corticosteroid 
after being told of the possible side effects. Six patients did not wish to participate in the 
trial. 
Twenty seven patients were randomly assigned to active treatment and twenty six were 
assigned to placebo. Four patients were withdrawn from the study; two in the 
corticosteroid group (day four and day five) and two in the placebo group (day three and 
day five). Two patients in the corticosteroid group had severe gastrointestinal upset. 
However, oesophagogastroduodenoscopy which was done for both patients were normal. 
One patient in the placebo group died due to acute extensive myocardial infarction. The 
other patient had asked to be withdrawn because he didn't feel better after treatment in 
the ward. 
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Figure I : Trial Profile 
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